SOCE (2-7)
. Upon calcium depletion from the cisternae delimited by the endoplasmic reticulum (ER) membrane, STIM1, which resides in this membrane forms oligomers and migrates to be adjacent to the plasma membrane (8) (9) (10) , where it activates Orai1, resulting in calcium influx (11, 12) .
In resting cells, the free calcium concentration in cytosol is maintained at an extremely low level, near 100 nM. This requires prompt inactivation of Orai1 leading to cessation of Ca 2+ entry, a process called calcium-dependent fast inactivation (CDI). Lewis and colleagues showed that calmodulin (CaM) and a cytosolic domain of STIM1 are important for CDI. They further showed that binding of CaM to an Nterminal fragment of Orai1 adjacent to its first transmembrane helix is calcium-dependent and critical for CDI (13) . It remains unknown, however, how CaM interacts with Orai1 to inactivate it.
CaM interacts with a large number of proteins to regulate their biological functions. It is composed of N-and C-terminal lobes (CaM-N and CaM-C) that are connected by a central linker. Structures of Ca 2+ -free and Ca 2+ -bound CaM show that upon calcium binding, CaM-N and CaM-C undergo conformational changes to expose a hydrophobic pocket in each lobe for the binding of target proteins (14) (15) (16) . In the absence of target proteins, the central linker of CaM is flexible in solution, and CaM-N and CaM-C do not interact with each other. In the presence of target proteins, CaM-N and CaM-C of a CaM molecule typically wrap around the CaM binding domains (CMBDs) of target proteins (usually an α helix) in a collapsed 1:1 binding mode. Exceptions, however, have been reported, in which CaM binds its target CMBDs in a 2:2 or 1:2 binding mode. For example, in the case of the small conductance Ca 2+ -activated potassium channel SKca, three helices are bound between CaM-N and CaM-C in an extended 2:2 binding mode (17);
In the case of glutamate decarboxylase, each lobe of CaM binds one peptide of glutamate decarboxylase, with the two peptides interacting with each other, resulting in a collapsed 1:2 binding mode (18) . The different structures of CaM/CMBD complexes indicate that CaM is very flexible allowing it to adopt different conformations. This conformational flexibility is consistent with the lack of sequence homology among CMBDs of its target proteins. The conformational flexibility of CaM and the lack of sequence homology among CMBDs make it difficult to use existing structural information to accurately predict the interaction between CaM and the CMBD of Orai1. We therefore carried out structural studies on the CaM/Orai1-CMBD complex, hoping to 1) understand how CaM facilitates CDI of Orai1; 2) add to our knowledge of the interaction modes of CaM with its target proteins.
Here, we report the crystal structure of Ca 2+ / CaM in complex with Orai1-CMBD at 1.9Å resolution. The structure shows that in the crystal Orai1-CMBD is bound only to CaM-C, with residue W76 of Orai1-CMBD fitting into the hydrophobic pocket of CaM-C and making extensive interactions with hydrophobic residues of CaM. Further biochemical analyses and mutational studies indicate that in solution CaM interacts with Orai1-CMBDs in a 1:2 binding mode, with CaM-N and CaM-C each binding one Orai1-CMBD.
MATERIALS AND METHODS
Materials--All chemicals were purchased from Sigma-Aldrich unless indicated elsewhere. All restriction enzymes were purchased from New England Biolabs. Crystallization chemicals were purchased from Hampton Research. The Orai1-CMBD peptide, (sequence: HSMQALSWRKLYLSRAKLKA), corresponding to residues H69-A88 of Orai1, was obtained from GenScript USA Inc., Cloning, expression and purification of CaM and CaM (Ca 2+ -N mut ) --The rat CaM cDNA was amplified by PCR using Supermix solution (Invitrogen) and cloned into pET21b vector using NdeI and BamHI restriction enzymes. CaM(Ca 2+ -N mut ), a CaM mutant with abolished Ca 2+ binding capacity at its N lobe, was constructed by mutating D20, D22, D24, E31, D56, D58, N60 and E67 to histidines. Primers containing the mutations were synthesized by Sigma. The mutant gene was amplified using multi-step PCR, and cloned into pET21b as wild type CaM. The plasmids CaM-pET21 and CaM(Ca 2+ -N mut )-pET21 were sequenced to confirm that the gene was correctly inserted. The plasmids were transformed into BL21 (DE3) Gold (Agilent Technologies) for protein expression. The bacteria were grown in LB medium at 37ºC, 220 rpm until cell density reached A 600nm =0.6. The bacteria were then cultured at 23ºC for 30 min before induction with 0.2 mM IPTG (Invitrogen). The culture was continued at 23ºC, 170rpm for another 4 hours. The bacteria were harvested by centrifugation at 4,000 rpm for 10 min. Cell pellets were kept at -80ºC until further use. CaM and CaM(Ca 2+ -N mut ) was purified according to a reported method (19) . Briefly, 1g portions of frozen cell pellets were suspended in 20 ml of Lysis Buffer (50 mM Tris, pH7.5, 2 mM EDTA, 0.2 mM PMSF). The bacteria were lysed by sonication. The lysate was centrifuged at 16,000 rpm for 20 min to remove cell debris. The supernatant was supplemented with 5 mM CaCl 2 before it was loaded onto a 5-ml HiTrap Phenyl HP column (GE Healthcare). The column was then washed with 50 ml Phenyl Wash Buffer 1 (50 mM Tris, pH 7.5, 0.1 mM CaCl 2 , 100 mM NaCl), followed by a wash with 50 ml Phenyl Wash Buffer 2 (50 mM Tris, pH 7.5, 5 mM CaCl 2 , 500 mM NaCl). The column was eluted with Phenyl Elute Buffer (50 mM Tris, pH7.5, 1 mM EGTA). The eluate was concentrated and further purified on a Superdex 200 column (GE Healthcare) equilibrated with Sizing Buffer (10 mM Tris pH7.5, 2 mM CaCl 2 , 100 mM NaCl).
Expression and purification of CaM-N, CaM-C, Orai1-CMBD and Orai1-CMBD(W76E)--CaM was also cloned into pGEX-4T1 vector using BamHI and XhoI restriction enzymes. To obtain CaM-N (aa 1-75), a stop codon was added after K75 in the CaM-pGEX plasmid using Quickchange mutagenesis kit (Agilent Technologies). The same strategy was used to make CaM-N-pET21 plasmid from CaM-pET21. The gene of CaM-C (aa 79-148) was amplified by PCR from CaM-pET21 and cloned into pET28b (Novagen) with a His-tag at its Nterminus using NheI and BamHI restriction enzymes. Orai1-CMBD (aa 69-91) was cloned into pET32b vector (Novagen) using NcoI and EcoRI restriction enzymes as a thioredoxin fusion protein (Orai1-CMBD-Trx) with a His-tag. Orai1-CMBD(W76E) was made from Orai1-CMBD-pET32 plasmid using Quickchange mutagenesis kit. All these constructs were expressed in E. coli BL21 (DE3) Gold (Agilent Technologies) in the same way as described above for the expression of CaM. CaM-N-GST fusion protein was loaded onto a GSTrap HP column (GE Healthcare), which was then washed with 10 column volumes of GSH Wash Buffer (20 mM Tris-HCl, pH7.5, 50 mM NaCl, 2 mM CaCl 2 ), and eluted with GSH Elution Buffer (100 mM Tris-HCl, pH7.5, 50 mM NaCl, 2 mM CaCl 2 , 10 mM GSH). CaM-C and Orai1-CMBDTrx were purified on a HisTrap FF column (GE Healthcare), which was washed with Ni Wash Buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 2 mM CaCl 2 , 20 mM imidazole), and eluted with Ni Elution Buffer (20 mM Tris-HCl, pH7.5, 500 mM NaCl, 100 mM EDTA). All eluates were concentrated using Amicon concentrators and further purified on a Superdex 200 column equilibrated with Sizing Buffer.
Crystallization of CaM/Orai1-CMBD complex--Peak fractions of CaM from Superdex 200 column were pooled and concentrated to 10~20 mg/ml using an Amicon concentrator. The Orai1-CMBD peptide powder was dissolved in Sizing Buffer, and mixed with CaM at a 2:1 molar ratio. Initial crystallization trials were screened around the reported conditions for CaM and CaM/target peptide complexes. Clusters of long needles were initially obtained in 0.1 M BisTris-HCl (pH 6.0), 45% polypropylene glycol P400 (PPG P400) at 4ºC. Optimization of crystallization was carried out using an Additive Screen (Hampton Research) with a Mosquito liquid handling system (TTP Labtech). Microseeding significantly facilitated crystal growth of CaM/Orai1-CMBD. Single needle crystals were obtained using 1 µl Calmodulin (20mg/ml) + synthetic Orai1-CMBD at 1:4 CaM to peptide molar ratio in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM CaCl 2 , mixed with 1 µl reservior solution (0.1 M Bis-Tris-HCl (pH 6.0), 40% PPG P400, 14% γ-butyrolactone, 1% n-octyl-β-D-glucopyranoside), and equilibrated against 500 µl reservoir solution at 20ºC by the hanging drop vapor diffusion method.
Data collection and processing--Crystals of CaM/Orai1-CMBD were flash frozen in liquid nitrogen without additional cryo-protectant. Xray diffraction data were collected using in-house x-ray generator MicroMax-007 HF (Rigaku). The crystals diffracted to 1.9 Å in space group C2, with cell dimensions of a=100.07 Å, b=24.71 Å, c=60.90Å, and β=100.1º. The data was processed and scaled with DENZO/SCALEPACK (20) . The statistics of the diffraction data are summarized in Table 1 .
Structure determination and refinement--The structure was solved by molecular replacement (MR) using PHASER MR from PHENIX program (21) . Initial search with CaM from the CaM/MARCKS structure (PDB code: 1IWQ) as a search model did not yield a solution. When CaM-N (aa4-75) and CaM-C (aa85-146) were used as individual search models, we were able to find rotation and translation solutions for molecular replacement. After several rounds of refinement using PHENIX and manual model building with COOT (22) , the central linker of CaM and Orai1-CMBD were successfully built into the electron density map.
Four γ-butyrolactone molecules were also built and refined. The statistics of refinement are shown in Table 1 . The interaction interfaces were analyzed with PISA program in CCP4 Molecular Graphics Documentation (23) .
All the graphic presentations of structures were made with Pymol (DeLano, W.L. The PyMOL molecular graphics system (2002) http://www.pymol.org).
Pull-down assays--In pull-down assays for synthetic Orai1-CMBD, 50 µl of 50 µM CaM-N-GST or CaM-C-His6 were mixed with 50µl of 50 µM Orai1-CMBD. All samples were in Sizing Buffer. 50 µl of GSH resin or nickel resin was added to mixtures of CaM-N-GST+Orai1-CMBD or CaM-C-His6+Orai1-CMBD, respectively. The mixtures were incubated on ice for 20 min, and centrifuged at 2,000 rpm for 3 min. The supernatants were removed and the resins were washed three times with 1 ml of GSH Wash Buffer or Ni Wash Buffer. 100 µl of 2xSDS sample buffer was added to each resin. The resins were spun at 16,000xg for 1 min and the supernatants were loaded onto SDS-PAGE gel.
The pull-down assays testing for interaction of CaM and CaM-N with recombinantly expressed wild type (WT) Orai1-CMBD-Trx or Orai1-CMBD(W76E)-Trx mutant were carried out in a similar manner as described above. Orai1-CMBDs were expressed as His6-tagged thioredoxin fusion proteins. WT and W76E Orai1-CMBD were incubated with GSH and Ni resins as a control to test the non-specific binding.
Isothermal titration calorimetry (ITC)
experiments--ITC measurements were carried out in Sizing Buffer using an iTC 200 MicroCalorimeter (GE Healthcare) at 25C. Substrate solutions containing synthetic or recombinantly expressed Orai1-CMBD at 0.3 to 1 mM were injected into a reaction cell containing 30 to 60 µM CaM, CaM-N or CaM-C. Fifty injections of 0.4 to 0.7 l at 120-second intervals were performed. Data acquisition and analysis were performed using the Origin Scientific Graphing and Analysis software package (OriginLab). Data analysis was performed by generating a binding isotherm and best fit using the following fitting parameters: N (number of sites), H (cal/mol), S (cal/mol/deg) and K (binding constant in M -1 ) and the standard Levenberg-Marquardt methods (24) . Following data analysis,
Determination of protein concentrationsCaM has a low extinction coefficient due to the lack of tryptophan, the main contributor for UV absorbance of a protein at 280nm. Therefore, CaM concentration calculated with extinction coefficient is susceptible to influence of contaminating proteins or DNA. The accuracy of protein concentration is critical for ITC data analysis.
Therefore, we determined CaM concentration using BCA (bicinchoninic acid) protein assay kit (ThermoScientific). BSA at different concentrations determined by weight over volume was used as standard.
The concentrations of His-tagged CaM-C, CaM-N-GST and synthetic Orai1-CMBD were also determined using the same BCA method.
Calculation of molecular weights by size exclusion chromatography--Bio-Rad gel filtration standard containing bovine thyroglobulin (670 kD), bovine γ-globulin (158 kD), chicken ovalbumin (44 kD), horse myoglobin (17 kD), and vitamin B 12 (1350 D) were run on Superdex 200 column eluted with Sizing Buffer. The log 10 (MW) were plotted against the elution volumes to obtain a standard curve. The molecular weights of protein samples were calculated by interpolation based on their elution volumes.
NMR Assignments-Calmodulin and CaM-N in pET21 vector were expressed in BL21 (DE3) Gold in minimal media containing U-[
13 C] glucose and 15 NH 4 Cl, and purified as described above. Prior to the NMR experiments the protein was concentrated to 60 µM. NMR spectra were acquired with Orai1-CMBD at 0, 30, 60, 90, and 120 µM. The experiments to assign the protein resonances were acquired in the presence of Orai1-CMBD at 120 µM. The buffer was: 10 mM NaP i pH 6.5, 2 mM CaCl 2 , 5% D 2 O, 50 µM 5,5-dimethylsilapentanesulfonate (DSS) to serve as a chemical shift reference. NMR spectroscopy was performed at 25 °C on Varian UNITY INOVA 500 MHz spectrometer equipped with a 5-mM triple resonance cold probe with actively shielded z-axis gradients. The NMR data were processed with NMRPipe (25) and the spectra were analyzed with NMRView (26) .
The backbone resonance assignments were made from analysis of the HNCACB, and CBCA(CO)NH experiments acquired using the Varian BioPack pulse sequences. Assignment of the methyl resonances was completed with the HCCH-TOCSY, H(CCO)NH-and C(CO)NH-TOCSY experiments using the standard Varian sequences. The filtered NOE experiments were performed for the mixture of 700 µM CaM and 700 µM Orai1-CMBD or for the mixture of 250 µM CaM-N and 300 µM Orai-CMBD with a 200 ms mixing time (27) .
RESULTS
Orai1-CMBD interacts only with CaM-C in crystal--We have determined the structure of CaM/Orai1-CMBD in the presence of Ca 2+ in space group C2 at 1.9Å.
There is one CaM/Orai1-CMBD complex in one asymmetric unit. The final R/R free factors are 0.18/0.21 (Table  1 ). There are four calcium ions bound to CaM, two to each lobe. Residues 3-146 of CaM are well defined by the electron density map, and all residues from Orai1-CMBD fit well to the electron density map. The overall quality of the electron density is good ( Fig. S1 in supplemental  data) .
Surprisingly, CaM adopts an extended conformation in the complex, with its central linker forming an α helix ( Fig. 1A and 1B) . The structure of CaM here is almost identical to Ca 2+ /CaM that is free of ligand (PDB code: 3CLN) (28) (Fig. 1C) . When our structure and that of ligand-free Ca 2+ /CaM were superimposed along their Cα, the superposition gave an RMSD of 0.44Å over 127 Cα. In fact, upon structural superposition, the surface of the C-lobe of Ca 2+ /CaM accommodates Orai-CMBD well, indicating that their side chains also adopt similar conformations.
The major change in the hydrophobic pocket of CaM-C is the side chain of F92 that rotates about 90º along the Cβ-Cγ bond to accommodate the side chain of L79 of Orai1-CMBD (Fig. 1D) . In one asymmetric unit, only CaM-C interacts with Orai1-CMBD; CaM-N has no interaction with either Orai1-CMBD or CaM-C. Orai1-CMBD, however, interacts with CaM-N of a symmetry-related CaM molecule (Fig. S2) .
This interaction consists of a hydrophobic interaction (between L81 of Orai1-CMBD and L4 and L70 of CaM) and two hydrogen bonds (CaM K13 NE -Orai1-CMBD K87 O, and CaM D64 OG1 -Orai1-CMBD K78 NE) (Fig. S2A) . The interface of CaM-C and Orai1-CMBD has a higher shape complementarity than that of Orai1-CMBD and symmetry-related CaM-N, resulting in a surface area of 780 Å 2 for Orai1-CMBD/CaM-C interaction, and 420 Å 2 for Orai1-CMBD/symmetry-related CaM-N interaction ( Fig. S2B and S2C ). Shape complementarity analysis using PISA server from CCP4 (web link: www.ebi.ac.uk/msd-srv/prot_int/pistart.html) indicates that Orai1-CMBD interaction with the N-lobe of symmetry-related CaM is unlikely to exist in solution. In addition, size exclusion chromatography of CaM/Orai1-CMBD complex does not show the existence of a dimeric complex, which would have been formed by this interaction. Thus the interaction of Orai1-CMBD with CaM-N observed in the crystal structure is simply a consequence of crystal packing.
Orai1-CMBD adopts partially a helical and partially an extended conformation--The Nterminal part of the peptide (residues 69-74) adopts an extended conformation. Some residues (H69, Q72 and A73) on this segment of the peptide interact with neighboring CaM and Orai1-CMBD molecules resulting from crystal packing. The C-terminal segment of Orai1-CMBD adopts α helical conformation. Most of the residues interacting with CaM are located in this helical segment (Fig. 1A and 1B) .
Orai1-CMBD interacts with CaM-C mainly through hydrophobic interactions--Residues W76 and L79 of Orai1-CMBD bind to the hydrophobic pocket of CaM-C (Fig. 2A) . The side chain of W76 is deeply buried in this pocket (Fig. 2B) , interacting with residues I100, L105, M124, I125, A128, V136, F141, and M144 of CaM. NOE signals confirm the interaction of W76 with I100, M124, I125, V136 and M144 (see below). L79 of Orai1-CMBD interacts with a hydrophobic surface that is composed of residues F92, L105, V108, M109 and L112 of CaM-C (Fig. S3B) . Thus, W76 and L79 of Orai1-CMBD make the major contribution to its interaction with CaM. In addition, L74 of Orai1-CMBD makes hydrophobic interactions with residues M109, E114, L116 and M124 of CaM, and Y80 of Orai1-CMBD interacts with I85, A88, F141 and M145 of CaM ( Fig. S3A and S3C) .
CaM-N binds Orai1-CMBD in solution--In the crystal structure, CaM-N interacts with Orai1-CMBD from a symmetry-related complex. In order to evaluate the interaction of Orai1-CMBD with CaM-N, we expressed and purified CaM-N (aa1-75) as a GST fusion protein and CaM-C (aa 79-148) with a His-tag. The individual lobes of CaM were used to pull down the synthetic Orai1-CMBD. Orai1-CMBD was pulled down not only by CaM-C, but also by CaM-N (Fig. 3A) . It is noteworthy that the controls for the pull-down assay indicate a non-specific binding of Orai1-CMBD to GSH resin. However, the nonspecifically bound Orai1-CMBD was removed from GSH resin during the wash. Thus, Orai1-CMBD was indeed pulled down by CaM-N GST fusion protein. ITC experiments also showed that both CaM-N and CaM-C alone bound Orai1-CMBD, with a K d of 4.6 µM for CaM-N, and 1.1 µM for CaM-C (Fig. 4) . This indicates that CaM-N alone can bind Orai1-CMBD, but with a slightly weaker affinity than CaM-C. The binding of CaM-N to Orai1-CMBD detected by pull-down assays and by ITC suggested that the interaction between CaM-N and Orai1-CMBD observed in crystal packing might contribute to the interaction in solution. However, when we mutated Trp76 of Orai1-CMBD to Glu, a mutation reported to abolish the binding of Orai1-CMBD to CaM and thus disrupt CDI (13), the pull-down assay (Fig. 3B) and ITC results (data not shown) showed that W76E mutant of Orai1-CMBD did not bind to CaM, CaM-N or CaM-C, indicating that the interaction of CaM-N with Orai1-CMBD observed at the lattice contact, which does not involve W76 of Orai1-CMBD, differs from the interaction observed in solution. Based on these data, we concluded that CaM-N and CaM-C both bind Orai1-CMBD through W76, with CaM-C having a higher affinity than CaM-N. Since CaM-N and CaM-C share high sequence homology, we superimposed CaM-N structure to CaM-C, and noticed that W76 of Orai1-CMBD also fits into the hydrophobic pocket of CaM-N ( Fig. 2C and 2D ), making W76 a ligand for for both CaM-N and CaM-C.
CaM binds Orai1-CMBD at a 1:2 ratio--The binding of CaM-N and CaM-C to Orai1-CMBD described above suggests that full length CaM binds Orai1-CMBD at a 1:2 ratio in solution, and that the crystal structure reflects an intermediate toward this 1:2 complex. Indeed, ITC data show that one CaM molecule binds two Orai1-CMBDs with a K d of 1.3 µM (Fig. 4) .
To further confirm the 1:2 binding ratio of CaM to Orai1-CMBD, we checked the complex formation of CaM with Orai1-CMBD-Trx fusion protein (Orai1-CMBD fused to the C-terminus of thioredoxin encoded in the pET32 vector) by size exclusion chromatography (Fig. 5) . Purified Orai1-CMBD-Trx, CaM and the mixture of these two proteins were individually run on Superdex 200 column, and their molecular weights were calculated from the elution volumes using a standard curve. CaM has a theoretical molecular weight of 16.7 kD, and Orai1-CMBD-Trx of 19.1 kD. Their molecular weights calculated from size exclusion chromatograms are consistent with their theoretical molecular weights (Fig. 5) . The calculated molecular weight of CaM is 20 kD, slightly higher than the theoretical value. This could be due to the elliptical rather than the globular shape of CaM in the absence of target peptide. The calculated molecular weight of Orai1-CMBD-Trx is 16 kD, slightly smaller than the theoretical value. At 1:1 molar ratio, the calculated molecular weight of CaM/Orai1-CMBD-Trx mixture is 43 kD, a number between the molecular weights of 1:1 and 1:2 CaM/Orai1-CMBD complexes. Because the affinity of Orai1-CMBD to CaM-C is only 4 fold stronger than that to CaM-N, at 1:1 molar ratio, a major fraction of Orai1-CMBD-Trx will bind to CaM-C, and the other fraction of Orai1-CMBD-Trx will bind to CaM-N, resulting in a mixture of 1:1 and 1:2 complexes. We suggest that there is equilibrium between the 1:1 and 1:2 complexes. This suggestion is supported by the NMR chemical shift perturbation data in Fig. 6 , which indicate weak binding of CaM-N to Orai1-CMBD with an intermediate exchange rate. This model is consistent with our failure to observe two separate peaks for 1:1 and 1:2 complexes on the size exclusion chromatogram of the 1:1 mixture. The calculated molecular weight of CaM/Orai1-CMBD-Trx mixture at 1:2 molar ratio is 48 kD, indicating a 1:2 CaM/Orai1-CMBD-Trx complex. When CaM and Orai1-CMBD-Trx were mixed at 1:4 molar ratio, an additional elution peak containing Orai1-CMBDTrx appeared, representing the excess of Orai1-CMBD-Trx. These results indicate that CaM and Orai1-CMBD-Trx form a 1:2 complex, rather than a 1:1 complex. Because Orai1-CMBD does not form dimers or oligomers, as indicated by its size exclusion chromatogram, we propose that upon binding to Orai1-CMBD, CaM remains in its extended conformation.
The property of proteins can make the elution volume on size exclusion chromatography deviate from regular elution volume, resulting in wrong calculated molecular weight. To rule out this possibility, we mutated the two calcium binding sites in CaM-N. The mutant, CaM(Ca 2+ -N mut ), will have only CaM-C capable of binding to Orai1-CMBD, and therefore can only form a 1:1 complex with Orai1-CMBD. When we subjected the 1:1 molar ratio mixture of CaM(Ca 2+ -N mut )/Orai1-CMBD-Trx to size exclusion chromatography, the calculated molecular weight of the complex was 35 kD, corresponding to the 1:1 complex (Fig. 5B ). At 1:2 molar ratio of CaM(Ca 2+ -N mut )/Orai1-CMBDTrx, an additional peak corresponding to free Orai1-CMBD-Trx appeared, and no complex appeared larger than the 1:1 complex formed (Fig. 5B ). At 1:4 molar ratio of CaM(Ca 2+ -N mut )/Orai1-CMBD-Trx, the dominant peak on size exclusion chromatogram was the free Orai1-CMBD-Trx (Fig 5B) . These results confirmed that the complexes in the 1:2 and 1:4 CaM/Orai1-CMBD-Trx mixtures observed on size exclusion chromatograms were 1:2 CaM/Orai1-CMBD-Trx complexes.
NMR data provided confirmation of the binding of two peptides to one CaM, and confirmed that CaM-N has a weaker affinity than CaM-C for Orai1-CMBD. Fig. 6 tracks a representative resonance from the 15 N-1 H HSQC of CaM-C (I130) and CaM-N (A57) upon titration of Orai1-CMBD using full length CaM. The full 15 N-1 H-HSQC is provided in supplemental materials (Fig. S4) . Fig. 6A shows two peaks for I130 at a 1:0.5 molar ratio of CaM/Orai1-CMBD mixture indicative of slow exchange between a bound and unbound conformation for I130; this is common for tight binding. At a 1:1 ratio, the C-terminal domain is fully saturated and the peak changes very little upon further addition of peptide to 1:1.5 and 1:2 molar ratios. In comparison, Fig. 6B shows that the A57 peak from the N-terminal domain broadens slightly at 1:0.5 and 1:1 but broadens significantly at 1:1.5, but does recover full intensity when a ratio of 1:2 is reached. This result indicates that binding to the C terminal domain is tighter and occurs first in the titration. The broadening of the amide resonances of the N terminal domain upon addition of peptide can also be observed with the CaM-N construct (Fig.  6C) . At a 1:0.5 ratio, the A57 peak of CaM-N is broadened due to intermediate exchange, consistent with a weaker binding to this domain. The difference is most striking between the I130 of full length CaM and the A57 of CaM-N at the same molar ratio (Fig. 6A and 6C ). Based on these comparisons, it appears that Orai1-CMBD interacts independently with the N and C terminal domains.
To model the interactions of the N terminal domain with the peptide, the N-terminal domain was superimposed on the C-terminal domain with the peptide bound to it. Inspection of this model suggests that several methyl groups of the Nterminal domain would potentially interact with W76 of Orai1-CMBD, particularly I27, L32, I52, V55, and I63 (Fig. 2D) . Indeed, an examination of methyl region of the 13 
C-
1 H HMQC spectra in Fig. 7A showed that the resonances of I52, and I63 shift considerably upon addition of Orai1-CMBD to CaM-N. To confirm this interaction in full length CaM, Fig. 7B shows similar shifts for resonances of the N-terminal domain, at a ratio of 1:2 CaM : Orai1-CMBD.
In order to more precisely understand the sites of interaction, an isotope-filtered NOESY study was performed, with 13 C, 15 N doubly labeled protein and the unlabeled Orai1 peptide.
This allows for detection of intermolecular signals that connect the resonances in the (labeled) calmodulin with resonances in the (unlabeled) peptide. There were clear signals from C-terminal lobe M124, M144, Ile100, Ile125, and Val136 to aromatic proton shifts typical of a tryptophan side chain; W76 is the only tryptophan in Orai1-CMBD (Fig. 8A) . This is consistent with what we observed in the crystal structure (Fig. 2B) . Isotope-filtered NOEs were also detected between CaM-N alone and Orai1-CMBD. Fig. 8B shows the interactions of W76 of Orai1-CMBD with N-terminal L32 of CaM. This is consistent with the homology model described above (Fug, 2D) . However, we did not observe NOE signals between W76 of Orai1-CMBD and other residues in the hydrophobic pocket of CaM-N (see discussion below). In total, these results confirm that CaM interacts with two Orai1-CMBD peptides via the N and C terminal domains, and that CaM-N has a weaker affinity for the peptide than CaM-C.
Structure of Orai1-CMBD reveals a modified helical wheel for interaction with camodulin--
Most of calmodulin binding domains adopt a helical structure. Mullins et al. predicted a helical wheel model of Orai1-CMBD (13) . Based on the crystal structure (Fig. 9A) , we made a helical wheel presentation of Orai1-CMBD (Fig. 9B) , and compared it with the helical wheel model predicted by Mullins et al (Fig. 9C) . The helical part of the peptide in the structure is in agreement with the prediction. However, the residues N-terminal to S75 of Orai1-CMBD adopt an extended conformation in crystal structure (Fig. 9B) , rather than the predicted helical conformation (Fig. 9C) .
DISCUSSION
Unique binding mode of Orai1-CMBD to CaM--We show a unique binding mode of CaM to the target peptide Orai1-CMBD: binding of one peptide to each lobe of CaM. (Fig. 10A) . The binding mode observed here is unique in two aspects: each lobe of CaM binds one target peptide to form a 1:2 complex; and CaM adopts an extended conformation in the complex rather than a collapsed confomation. It is well known that CaM has plasticity to bind different target peptides. Based on the numbering of residues of CMBDs that are critical for interaction with CaM-N and CaM-C, CaM target peptides can be divided into different groups: 1-7, 1-10, 1-14, 1-16, and 1-18 ( Fig. 10B) (29, 30) . Because each Orai1-CMBD interacts with only one lobe of CaM, we categorize it as group 1-0. To date, there has been only one structure of 1 CaM: 2 target peptides reported that falls into this group, CaM/glutamate decarboxylase (GAD)-CMBD (Fig. 10B) . The structure of this CaM/GAD complex shows that CaM-N and CaM-C each binds one GAD-CMBD. The two GAD-CMBDs interact with each other to induce CaM to adopt a collapsed conformation (Fig. 10C) (18) . CaM-N and CaM-C interact with GAD-CMBD in similar ways. The tryptophan residue on GAD-CMBD, however, is not deeply buried in the hydrophobic pocket of CaM-N or CaM-C (Fig. 10D) . CaM/Orai1-CMBD may resemble the structure of CaM/GAD-CMBD in that Orai1-CMBD interacts with CaM-N and CaM-C in similar ways. The extended conformation in CaM/Orai1-CMBD complex instead of a collapsed conformation (Fig. 10A) may result from the fact that Orai1-CMBD does not form a dimer in solution (Fig. 5) as GAD-CMBD does. Therefore, CaM/Orai1-CMBD displays a unique binding mode of CaM to its target peptides, and again shows the flexibility of CaM to bind a large variety of target proteins. In addition to Orai1-CMBD and GAD-CMBD, IQ calmodulin binding peptides from NaV1.5(31), NaV1.2(32) and PEP-19 (33) (34) (35) , bind selectively to the C lobe of CaM, leaving the N lobe unoccupied, and thus fall in this group 1-0.
The NMR studies indicate that the interactions of each lobe of the calmodulin with the Orai1-CMBD are homologous, so that the two binding lobes each compete for the same set of residues. This type of interaction requires that binding be sequential, with the first Orai1-CMBD interacting with the stronger binding C-terminal lobe, and the second binding event involving the N-terminal lobe. This sequential binding effect is particularly apparent from the titration study shown in Fig. 6 .
The first structure reported for CaM/PMCA-CMBD showed that CaM interacted with PMCA-CMBD through CaM-C only (36). Since the PMCA-CMBD used for their studies was a splice variant of PMCA lacking additional C-terminal residues (Fig. 10B) , it was suggested that the structure of the complex was an intermediate towards the collapsed structure (36). As shown in Fig. 10B , when additional residues were added, the residue Val could have served as a binding site for CaM-N, resulting in a collapsed complex, as observed in the structure of CaM/smMLCK complex (37) with CaM wrapped around the peptide. In reality, the anchor residue for CaM-N binding was a Phe rather than Val, 17 residues away from the anchoring Trp residue at CaM-C (Fig. 10 B) , creating a new 1-18 binding mode (38) . However, in our case, extension of residues at the C-terminus of Orai1-CMBD is not feasible as Orai1-CMBD is immediately Nterminal to the 1 st transmembrane helix (Fig.  11A) . Therefore, no additional residues can be added to the C-terminus of Orai1-CMBD to provide a binding site for CaM-N to allow CaM to adopt a collapsed structure without incurring a clash between CaM-N and plasma membrane.
Possible mechanism for Ca 2+ /CaMdependent inhibition (CDI) of Orai1--Based on this unique feature of the CaM/Orai1 interaction, we propose a mechanism for the CDI of Orai1. Orai1 exists as a dimer in resting state, and upon activation by STIM1, forms a tetramer (39) . STIM1 was reported to interact with the cytosolic N-and C-termini of Orai1 to activate ion flux (11, 12) . We therefore propose that CaM-C interacts with one subunit of Orai1 followed by CaM-N interacting with another adjacent subunit in the Orai1 oligomer (Fig. 11B) . In so doing CaM displaces STIM1 from interacting with Orai1, and thus inactivates the channel.
Interpretation of different binding affinities of Orai1-CMBD for CaM-N and CaM-C -ITC data showed that the binding affinity of Orai1-CMBD for CaM-C is four times stronger than that for CaM-N.
To interpret this difference, we superimposed CaM-N with CaM-C to obtain the model of CaM-N/Orai1-CMBD complex (Fig. 2) . By doing so, we noticed three significant clashes between CaM-N and the peptide (Fig. 2C) . Two of these clashes (between L74 of Orai1-CMBD and Q41 of CaM, and between Y80 of Orai1-CMBD and M72 of CaM) can be resolved by rotating the side chains of CaM residues to adopt different rotamer conformations. The third clash is between W76 of Orai1-CMBD with V55 in the hydrophobic pocket of CaM-N.
When we compared the hydrophobic pocket of CaM-N with that of CaM-C, we found that the amino acid compositions of the two pockets are identical except for two amino acids, V55(CaM-N)/A128(CaM-C) and I63(CaM-N)/V136(CaM-C). V55 has a more bulky side chain than A128, creating a clash with the side chain of W76 of Orai1-CMBD.
This clash, unlike the two mentioned above, cannot be resolved by rotating the side chain of V55. Thus, the side chain of V55 may prevent W76 of Orai1-CMBD from going deeply into the hydrophobic pocket of CaM-N, resulting in a weaker affinity. This proposal may also explain why we did not observe the NOE signals between W76 of Orai1-CMBD and M51, I52, I63, and M71 of CaM, whose equivalent residues in CaM-C show NOE signals with W76 of Orai1-CMBD ( Fig. 2B and  2D, Fig. 8) .
Interpretation of reported biochemical data of Orai1 inactivation using the structural information--The structure of CaM/Orai1-CMBD is consistent with the biochemical and electrophysiological data of Mullins et al (13) . First, in the structure, W76 of Orai1-CMBD interacts with a hydrophobic pocket of CaM-C. This hydrophobic pocket is made of side chains of residues I100, L105, M124, I125, A128, V136, F141 and M144 (Fig. 2B ). This shows that W76 is critical for the interaction of Orai1-CMBD with CaM. In fact, Mullins et al. showed that W76A, W76E and W76S mutants of Orai1, all lost their capability of binding to CaM, and CDI of Orai1 was abolished by these mutations (13) .
Y80 of Orai1 is another residue that was predicted to be important for interacting with CaM. When Y80 of Orai1-CMBD was mutated to Ser or Ala (13), Orai1 mutants retained their binding affinity for CaM, whereas the Y80E mutation disrupted the Orai1 interaction with CaM (13). In the structure, the aromatic ring of Y80 of Orai1-CMBD interacts with I85, A88, and F141 and M145 of CaM-C through hydrophobic interactions (Fig. S3C) . The hydroxyl group of Y80 also forms a hydrogen bond with backbone oxygen atom of E84 of CaM. Based on the structure, Y80A or Y80S mutation will not disturb this hydrophobic interaction significantly enough to disrupt the interaction of Orai1 with CaM. The electron density of OE1 and OE2 of E84 of CaM is not well defined, indicating the side chain of E84 adopts different rotamers in solution. When Y80 is mutated to Glu, there will be electrostatic repulsion between Y80E and E84 ( Fig. 2A) , which may be significant enough to disrupt the interaction between Orai1 and CaM. Alternatively, since Y80 is located in a hydrophobic environment formed by CaM residues (Fig. S3C) , the Y80E mutation will place the hydrophilic and charged side chain of glutamic acid in this hydrophobic environment, which will be disfavored, and thus disrupt the interaction between Orai1 and CaM.
A73 of Orai1 was the third amino acid that was predicted to interact with CaM. Mutation A73E also disrupts the interaction of Orai1 with CaM (13). In the crystal structure, A73 does not interact with CaM. However, the CB atom of A73 is 4.8 Å away from the OE2 atom of E123 of CaM ( Fig. 2A) . The A73E mutation will create electrostatic repulsion between E73 of the Orai1 mutant and E123 of CaM, disrupting the interaction of Orai1 with CaM. We predict that mutation of A73 to amino acids with short side chains, such as Ser, Val, or Thr, should not disrupt the interaction of Orai1 with CaM.
In summary, we show here that Orai1-CMBD binds to CaM through a unique binding mode: it interacting only with CaM-C in the crystal structure, but interacting with both CaM-N and CaM-C in solution, and forming a 1:2 CaM/Orai1-CMBD complex.
Based on the structure and biochemical data, we propose a mechanism for CaM to displace STIM1 and thus inactivate the Orai1tetramer: in a first step the Clobe of CaM would interact with the CMBD of one Orai1, which would be followed by interaction of the N-lobe of the same CaM with the CMBD of a neighboring Orai1 (Fig. 11B) . Our data cannot address whether one or two Ca 2+ /CaM complexes are required for channel Orai1 inactivation. The structural information is useful for further studies on understanding how Orai1, STIM1 and CaM interact with each other to carry out CDI. Orai1-CMBD can be pulled down by either CaM-N or CaM-C, suggesting that in solution CaM-N also interacts with Orai1-CMBD. As a control, the peptide was added to GSH resin or nickel resin in the absence of CaM-N or CaM-C. The control experiments showed a non-specific binding of Orai1-CMBD to GSH resin. However, this non-specifically bound peptide was washed off the resin during the wash. B. Pulldown of recombinantly expressed Orai1-CMBD or Orai1-CMBD(W76E) mutant by CaM-GST or CaM-N-GST with GSH resin. Wild type (WT) Orai1-CMBD can be pulled down by CaM or CaM-N, consistent with the pull-down results of the synthetic peptide. W76E mutation disrupts the interaction of Orai1-CMBD with both CaM and CaM-N, suggesting that both CaM-N and CaM-C bind to W76 of Orai1-CMBD. (13) . In both B and C, the residues are labeled with their amino acid numbers according to human Orai1 sequence. S75 is colored in red. Note that, N-terminal to S75, the crystal structure differs from the hypothetical model. The residues that reflect the discrepancy between the structure and the hypothetical model are colored in green. In all three panels, residues L74, W76 and L79 involved in hydrophobic interaction with CaM are boxed. by guest on September 16, 2017 
